Last reviewed · How we verify
DLBS3233
DLBS3233 is a bioactive fraction derived from Cinnamomum burmannii that modulates lipid metabolism and reduces hepatic steatosis through multiple pathways.
DLBS3233 is a bioactive fraction derived from Cinnamomum burmannii that modulates lipid metabolism and reduces hepatic steatosis through multiple pathways. Used for Non-alcoholic fatty liver disease (NAFLD).
At a glance
| Generic name | DLBS3233 |
|---|---|
| Also known as | Inlacin |
| Sponsor | Dexa Medica Group |
| Drug class | Herbal extract / Natural product |
| Modality | Small molecule |
| Therapeutic area | Hepatology / Gastroenterology |
| Phase | Phase 3 |
Mechanism of action
DLBS3233 contains polyphenolic compounds that inhibit hepatic lipogenesis and enhance fatty acid oxidation, thereby reducing intrahepatic triglyceride accumulation. It also exhibits anti-inflammatory and antioxidant properties that may ameliorate liver injury associated with non-alcoholic fatty liver disease (NAFLD).
Approved indications
- Non-alcoholic fatty liver disease (NAFLD)
Common side effects
- Gastrointestinal disturbance
- Abdominal discomfort
Key clinical trials
- The Effect of Therapy Combination in PCOS With Dlbs 3233 (EARLY_PHASE1)
- PCOS Treatment Using DLBS3233, Metformin, and Combination of Both (PHASE3)
- Efficacy and Safety of DLBS3233 in Subjects With Polycystic Ovary Syndrome (PCOS) (PHASE3)
- Efficacy and Safety of DLBS3233 in Subjects With New Onset of Type 2 Diabetes Mellitus (PHASE3)
- Efficacy and Safety of Add-on Therapy With DLBS3233 in Patients With Type-2 Diabetes Mellitus (PHASE3)
- Efficacy and Safety of DLBS3233 in Prediabetic Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DLBS3233 CI brief — competitive landscape report
- DLBS3233 updates RSS · CI watch RSS
- Dexa Medica Group portfolio CI